Kirby Reinecke
Medical · Canton, GANPI 1093047474
Payments from drug & device makers
Across 474 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$613
- Corcept Therapeutics$547
- Abbott$457
- Boehringer Ingelheim$453
- plus $4K from 45 others
What the payments were for
- Food & beverage$8,269100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,269 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 108 | $135,600 |
| OzempicSemaglutide | 79 | $135,300 |
| JardianceEmpagliflozin | 47 | $49,154 |
| FarxigaDapagliflozin Propanediol | 66 | $43,044 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $28,488 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $17,089 |
| VascepaIcosapent Ethyl | 17 | $13,708 |
| JanuviaSitagliptin Phosphate | 18 | $13,298 |
| TradjentaLinagliptin | 23 | $11,898 |
| SynthroidLevothyroxine Sodium | 146 | $9,587 |
| NovologInsulin Aspart | 11 | $4,711 |
| UnithroidLevothyroxine Sodium | 29 | $1,961 |
| Tirosint-SolLevothyroxine Sodium | 13 | $1,765 |
| TirosintLevothyroxine Sodium | 12 | $1,636 |
| Gabapentin | 11 | $783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,149 | $140,01190 claims |
| Lilly USA, LLCMounjaro | $1,103 | $135,600108 claims |
| Boehringer IngelheimJardiance, Tradjenta | $453 | $61,05270 claims |
| AstraZenecaFarxiga | $295 | $43,04466 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $613 | $28,48833 claims |
| MerckJanuvia | $113 | $13,29818 claims |
| AbbVieSynthroid | $60 | $9,587146 claims |
| IBSA Pharma Inc.Tirosint-Sol, Tirosint | $14 | $3,40125 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $99 | $2,30867 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.
Other medical in Canton
- Lisa WeissCanton$283K
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
- Danna Dennis-CalderAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.